- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued based on future growth
U.S. Pharmaceuticals & Biotech Undervalued based on future growth
Results
12
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
12 companies
Harmony Biosciences Holdings
Market Cap: US$2.2b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$37.38
7D
-2.0%
1Y
7.5%
Organon
Market Cap: US$1.9b
Develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.
OGN
US$7.24
7D
0.8%
1Y
-53.1%
Alvotech
Market Cap: US$1.6b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$5.00
7D
-4.9%
1Y
-62.3%
Collegium Pharmaceutical
Market Cap: US$1.5b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$45.53
7D
-8.6%
1Y
54.3%
Emergent BioSolutions
Market Cap: US$649.1m
A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.
EBS
US$12.51
7D
0.6%
1Y
21.2%
Zevra Therapeutics
Market Cap: US$504.4m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$8.34
7D
-6.0%
1Y
-2.9%
SIGA Technologies
Market Cap: US$437.5m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$6.27
7D
0%
1Y
-0.9%
Abeona Therapeutics
Market Cap: US$285.6m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$5.31
7D
-2.6%
1Y
-11.8%
Coherus Oncology
Market Cap: US$171.6m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.37
7D
3.0%
1Y
-17.5%
Protalix BioTherapeutics
Market Cap: US$144.8m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$1.74
7D
-3.9%
1Y
-17.9%
Atara Biotherapeutics
Market Cap: US$130.4m
Engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom.
ATRA
US$17.77
7D
2.9%
1Y
8.7%
Earth Science Tech
Market Cap: US$38.2m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.13
7D
-1.8%
1Y
8.4%